Recombinant human tissue plasminogen activator (rtPA), also commonly known as alteplase, is a medication used to dissolve blood clots. Here's a breakdown of its key functions and applications:
Mechanism of Action:
- rtPA is a lab-made version of a protein naturally present in the body called tissue plasminogen activator (tPA).
- tPA plays a crucial role in the blood clotting system by converting plasminogen (an inactive enzyme) into plasmin (the active enzyme responsible for clot breakdown).
- rtPA administration mimics this process, promoting clot dissolution.
Applications:
- rtPA is the only FDA-approved treatment for acute ischemic stroke caused by a blood clot blocking blood flow to the brain. Timely administration is critical for maximizing its effectiveness and minimizing brain damage.
- In some cases, rtPA might also be used for:
- Acute myocardial infarction (heart attack) with ST-segment elevation (STEAMI)
- Acute massive pulmonary embolism (large blood clot in the lung artery)
- Dissolving blood clots in certain central venous access devices (tubes placed in large veins)
Important Considerations:
- rtPA treatment has a time window. It's generally most effective when administered within 3-4.5 hours of stroke symptom onset. Early diagnosis and treatment are crucial.
- rtPA can be a life-saving treatment, but it also carries risks, including:
- Increased bleeding risk, especially in the brain (intracerebral hemorrhage)
- Allergic reactions
Not for Everyone:
- rtPA is not suitable for everyone due to the bleeding risk. People with certain medical conditions or a high risk of bleeding shouldn't receive it.